TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Procept BioRobotics Corp (PRCT) PT Raised to $94 at BofA Securities
August 22, 2024 5:36 AM EDTBofA Securities analyst Bob Hopkins raised the price target on Procept BioRobotics Corp (NASDAQ: PRCT) to $94.00 (from $80.00) while maintaining a Buy rating.
The analyst comments "This morning, PRCT announced that it received FDA clearance for Hydros its next generation robot for benign prostatic... More
PROCEPT BioRobotics Corporation (PRCT) Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
August 21, 2024 7:02 AM EDTPROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the Company), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is... More
